+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 501 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.

Age: 18Years - 80YearsAll GendersPhase 3
109 locations
E

Actively Recruiting

Researchers are exploring a new treatment for chronic myeloid leukemia CML, a type of blood cancer. The study aims to evaluate the safety and tolerability of different doses of MK-4208 Tern-701 and to identify the highest dose that participants can tolerate and that may be effective in treating CML. This trial is being conducted in phases 1 and 2 to gather important information about MK-4208s use in this disease. Participants will receive MK-4208 orally at various doses ranging from 160 mg to 500 mg, taken once or twice daily depending on the study part. The study includes multiple groups that receive different doses to compare safety and tolerability. Treatment duration and dosing schedules may vary across the study parts, with careful monitoring of participants during the intervention. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious side effects up to three years. Researchers will also track hematologic and molecular responses to the treatment and measure drug levels in the blood over time. Safety, tolerability, and efficacy data will be collected to better understand the potential role of MK-4208 in treating CML, with the study expected to last until 2030 for complete follow-up.

Age: 18Years +All GendersPhase 1Phase 2
54 locations
A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
E

Actively Recruiting

Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.

Age: 18Years +All GendersPhase 2
148 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of known ultraviolet UV radiation doses on individuals with light and dark skin types, assessing the protective effects of two different sunscreen products, a placebo, and a standard sunscreen. This Phase 4 clinical study aims to understand skin responses to UV exposure using an adaptation of FDA guidelines for over-the-counter sunscreen use. Approximately 70 participants with a variety of skin types will be enrolled to help gather diverse data. Participants will be randomly assigned to receive one of three interventions a Hybrid sunscreen SPF 30, a Chemical sunscreen SPF 30, or no sunscreen placebo. The study will measure skin protection and reactions before and after UV exposure, including visual assessments, Chromameter and Mexameter skin measurements, digital photography, and thermometer readings. Additionally, researchers will collect dermal interstitial fluid through micro-needling to analyze skin changes. Throughout the study, participants will undergo evaluations at baseline and again three days after treatment. These assessments include measuring skin color changes, erythema redness, and dermal darkening. Temperature readings will be taken immediately before and after UV exposure. Participants will be monitored for adherence to study instructions, including avoiding additional UV exposure and following clothing guidelines. The study is expected to be completed over a period from September 2026 to April 2027.

Age: 18Years - 75YearsAll GendersPhase 4
1 location
E

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.

Age: 50Years +All GendersPhase 2Phase 3
132 locations
E

Actively Recruiting

Researchers are evaluating a new treatment called MK-8748 for people with diabetic macular edema DME, a condition that can cause vision loss in people with diabetes. This trial compares MK-8748 to an existing standard treatment called aflibercept to see if MK-8748 works as well. The study is a randomized, double-masked, pivotal phase 3 trial focusing on treatment safety and effectiveness. Participants are assigned to one of three groups a low dose of MK-8748, a high dose of MK-8748, or the standard aflibercept treatment. Those receiving MK-8748 will get five initial injections every 4 weeks, then continue every 8 weeks until week 48, followed by personalized treatment intervals up to week 100. Participants in the aflibercept group receive injections every 4 weeks for five doses, then every 8 weeks up to week 100. During the study, participants will have regular eye exams and vision tests to measure changes in visual acuity and eye thickness. Researchers will monitor how well treatments reduce retinal swelling and improve diabetic retinopathy severity using imaging and questionnaires. Safety will be closely observed, including adverse events and antibody levels, over approximately two years. The main focus is to assess the change in best-corrected visual acuity from baseline to one year.

Age: 18Years +All GendersPhase 3
20 locations
W

Actively Recruiting

Researchers are evaluating a culturally-tailored home-based physical activity program designed for Hispanic or LatinoLatina adolescent and young adult childhood cancer survivors. These survivors may face long-term effects like weight gain, fatigue, and reduced physical fitness after cancer treatment. The study aims to see if this culturally-relevant program can help increase physical activity and improve overall health compared to using a Fitbit tracker alone. The study has two stages. In Stage 1, 20 Latinx survivors participate in developing the intervention using Fitbit trackers, text messages, social media support, wearable activity devices, and interviews over 9 months. In Stage 2, 170 survivors who do not meet physical activity guidelines are randomized to either the intervention group, which includes Fitbit use, weekly goal-setting, peer support via social media and Zoom meetings, and optional activity partners, or a control group that only uses Fitbit trackers for 12 weeks. The intervention includes an intensive phase with weekly sessions followed by a 4-week maintenance phase. Participants will wear Fitbit trackers daily and engage in goal-setting, peer discussions, and physical activity reminders. Researchers will measure moderate to vigorous physical activity, sedentary time, and health-related quality of life over 12 weeks. Additional evaluations include physiological markers of heart and metabolic health and qualitative interviews to improve the program. The study lasts through the intervention phases with ongoing monitoring and support for participants.

Age: 15Years - 20YearsAll GendersPhase 2
77 locations
S

Actively Recruiting

Researchers are evaluating a decisional support intervention called the University of Rochester-Geriatric Oncology assessment for Acute Myeloid Leukemia UR-GOAL compared to an attention control among older adults newly diagnosed with acute myeloid leukemia AML. This multicenter randomized controlled trial aims to assess whether UR-GOAL can reduce patient distress, improve shared decision making between patients, caregivers, and oncologists, and decrease decisional conflict. The study is sponsored by the University of Rochester and is conducted at four sites. Participants will be randomly assigned to one of two groups the UR-GOAL intervention or an attention control group. Patients in the UR-GOAL group will watch an AML-focused video, complete a best-worst scaling exercise to identify their care priorities, and receive a summary report to review and discuss during clinical visits. Caregivers, if available, will also watch the AML video and receive the summary report. Oncologists will receive a report summarizing the patients geriatric assessment, priorities, and prognosis perception. The control group patients and caregivers will watch a nutritional video, complete a nutrition questionnaire, and receive nutrition handouts for review and discussion. Oncologists in this arm will be provided with the patients nutrition questionnaire. Both arms involve reviewing these materials during upcoming clinical visits. Participants will be assessed at several time points including 1 month for distress, 2 weeks for shared decision making and decisional conflict, and observation of shared decision making at the start. All participants must be 60 years or older with a new AML diagnosis and have not started cancer-directed treatment except some temporary measures. The study involves questionnaires, videos, and discussions to measure decision-related outcomes. The total study duration extends to June 2030, with ongoing monitoring of patient distress and decision-making quality. Caregivers and oncologists also participate in aspects of the assessments and interventions.

Age: 60Years +All GendersPhase Not Applicable
4 locations

1-10 of 501

1